Phase I/II Study of the MEK Inhibitor Selumetinib Plus DS-8201a (Trastuzumab Deruxtecan) in KRAS-Mutant, HER2-Expressing Pancreatic Ductal Adenocarcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT07619521

Title field or adapter rule

{'original_value': 'Phase I/II Study of the MEK Inhibitor Selumetinib Plus DS-8201a (Trastuzumab Deruxtecan) in KRAS-Mutant, HER2-Expressing Pancreatic Ductal Adenocarcinoma', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:22.625726+00:00

Published At

2026-10-22T00:00:00+00:00

Record Updated At

2026-10-22

Source Retrieved At

2026-10-31T22:17:25.750886+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Advanced Pancreatic Ductal Adenocarcinoma", "Metastatic Pancreatic Ductal Adenocarcinoma", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Unresectable Pancreatic Ductal Adenocarcinoma"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-22", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT07619521"

protocolSection.identificationModule.officialTitle

"Phase I/II Study of the MEK Inhibitor Selumetinib Plus DS-8201a (Trastuzumab Deruxtecan) in KRAS-Mutant, HER2-Expressing Pancreatic Ductal Adenocarcinoma"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE1", "PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Advanced Pancreatic Ductal Adenocarcinoma (protocolSection.conditionsModule.conditions)
• Metastatic Pancreatic Ductal Adenocarcinoma (protocolSection.conditionsModule.conditions)
• Stage III Pancreatic Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
• Stage IV Pancreatic Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
• Unresectable Pancreatic Ductal Adenocarcinoma (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Treatment (Selumetinib and DS-8201a)'], 'description': 'Undergo blood sample collection', 'name': 'Biospecimen Collection', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Treatment (Selumetinib and DS-8201a)'], 'description': 'Undergo diagnostic imaging', 'name': 'Diagnostic Imaging Testing', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Treatment (Selumetinib and DS-8201a)'], 'description': 'Undergo echocardiography', 'name': 'Echocardiography Test', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Treatment (Selumetinib and DS-8201a)'], 'description': 'Undergo MUGA scan', 'name': 'Multigated Acquisition Scan', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Treatment (Selumetinib and DS-8201a)'], 'description': 'Given PO', 'name': 'Selumetinib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Treatment (Selumetinib and DS-8201a)'], 'description': 'Given IV', 'name': 'Trastuzumab Deruxtecan', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Selumetinib (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.